Our Partners & Stakeholders

At the heart of the UK Industry Pharmacogenetics Network (UK-IPN) lies a dynamic and growing community of partners who share a common vision: to embed pharmacogenetic testing into routine clinical care across the UK. 

Our partners span the breadth of the life sciences sector, including:

National Health Service (NHS)

Medicines and Healthcare products Regulatory Agency (MHRA)

Department of Health & Social Care (DHSC)

Health Innovation Networks (HINS)

Office for Life Sciences (OLS)

Association of British Pharmaceutical Industry (ABPI)

Association of British HealthTech Industries (ABHI)

British In Vitro Diagnostics Association (BIVDA)

Institute of Biomedical Science (IBMS)

In addition to:

- Medical device manufacturers

- Diagnostic and laboratory service providers

- Health tech and software innovators

- Pharmaceutical and biotech companies

- Academic institutions

Together, these organisations form a collaborative ecosystem that drives innovation, accelerates adoption, and ensures the delivery of safe, effective, and scalable pharmacogenetic solutions.

Why Partnership Matters

Pharmacogenomics is a cornerstone of precision medicine, and its successful integration into the NHS requires coordinated efforts across industry and the healthcare system. UK-IPN partners play a vital role in:

  • Co-creating clinical pathways that support the implementation of pharmacogenetic testing
  • Navigating regulatory frameworks to ensure compliance and patient safety
  • Contributing to national initiatives, CERSI PGx the UK Regulatory Science and Innovation Network in Pharmacogenetics and associated research projects.
  • Building trust and transparency around commercial involvement in genomic medicine

A Platform for Collaboration

UK-IPN provides a structured and inclusive platform for partners to engage with NHS leaders, government bodies, and fellow innovators. Through regular forums, working groups, and strategic projects, our partners help shape the future of pharmacogenomics in the UK.

We are proud to work alongside organisations that are committed to improving patient outcomes, advancing scientific excellence, and championing the role of industry in shaping healthcare in collaboration with the NHS. We strive to implement PGx as standard of care for all patients, in alignment with the NHS 10-year plan and the NHSE Genomic Strategy for pharmacogenetics for England and the devolved nations.